BRUKINSA is a prescription medicine. BRUKINSA is used to treat mantle cell lymphoma (MCL).
INDICATIONS AND USAGE
BRUKINSA is a kinase inhibitor indicated for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
DOSAGE FORMS & STRENGTHS
Capsules: 80 mg
Manufactured By: BeiGene
Prescribing Information URL: Click Here
South Delhi Pharma can facilitate the supply of “BRUKINSA ™ (zanubrutinib) capsules” to all locations in India and other part of countries after fulfilling the legal requirement (if applicable). All Anticancer drugs available upon request. To get best price please share your mobile number to receive quotes from South Delhi Pharma.
Get In Touch
Get in touch with us at South Delhi Pharma (SDP), and one of our team will be on hand to help with any queries you may have.
The SDM is open
Monday to Friday.
Business hours: 09:30 A.M to 18:30 P.M.
M:+91-9891296838 / P:+91-11- 26532129
Zanubrutinib, sold under the brand name Brukinsa, is a medication for the treatment of adults with mantle cell lymphoma (MCL) who have received at least one prior therapy.
It was approved for medical use in the United States in November 2019.
Zanubrutinib is classified as a Bruton's tyrosine kinase (BTK) inhibitor.